immunotherapy – Medxy AI

Predictive Power of MRI-Based Radiomic Dynamics for Pathological Complete Response in Hepatocellular Carcinoma: A Deep Learning Synthesis

By MedXY 03/15/2026

This review evaluates how deep learning-assisted delta radiomics on MRI, combined with AFP response, provides a non-invasive, high-accuracy prediction of pathological complete response in unresectable HCC undergoing conversion immunotherapy.

Hematology-Oncology news

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion

By MedXY 03/13/2026

A landmark study reveals that anti-BCMA bispecific antibodies, unlike anti-GPRC5D, deplete B-cell precursors from the small pre-B stage onward, explaining the significantly higher infection rates observed in multiple myeloma patients.

Gastroenterology news Oncology

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

By MedXY 03/12/2026

A breakthrough study reveals that the balance between FYN and LCK kinases acts as a metabolic switch in hepatocellular carcinoma. By modulating this axis through low-dose LCK inhibition, researchers successfully preserved T-cell stemness and mitochondrial health, significantly enhancing the efficacy of immune checkpoint blockade.

Gastroenterology news Oncology

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial

By MedXY 03/11/2026

This post-hoc analysis of the HIMALAYA Phase III trial explores the link between immune-mediated adverse events and overall survival in unresectable HCC, revealing that patients on the STRIDE regimen who experienced imAEs had improved survival outcomes compared to those who did not.

news Oncology Otorhinolaryngology

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma

By MedXY 03/09/2026

The 3-year follow-up of the RATIONALE-309 trial demonstrates that first-line tislelizumab plus chemotherapy significantly improves overall survival (45.3 months) in recurrent or metastatic nasopharyngeal carcinoma, identifying B-cell signatures as a key predictor of response.

Clinical Updates news Oncology

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling

By MedXY 03/07/2026

This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT1/STAT3 modulation.

news Oncology Urology

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease

By MedXY 03/04/2026

The SURE-02 phase 2 trial demonstrates that a combination of sacituzumab govitecan and pembrolizumab achieves a 39% clinical complete response rate in muscle-invasive bladder cancer, offering a promising bladder-sparing alternative for patients ineligible for cisplatin-based chemotherapy.

news Oncology Otorhinolaryngology

Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma

By MedXY 02/27/2026

Long-term results from the RATIONALE-309 trial show tislelizumab plus chemotherapy significantly improves survival in recurrent or metastatic nasopharyngeal carcinoma, establishing a durable therapeutic standard and identifying B-cell signatures as key biomarkers for treatment response.

Dermatology news Oncology

KEYVIBE-010: Why Adding TIGIT Inhibition to Pembrolizumab Failed to Benefit High-Risk Resected Melanoma Patients

By MedXY 02/26/2026

The Phase 3 KEYVIBE-010 trial demonstrates that adding vibostolimab to pembrolizumab in the adjuvant setting for melanoma does not improve outcomes, instead yielding a higher recurrence rate and increased toxicity, reinforcing pembrolizumab monotherapy as the standard of care.

Clinical Updates news Oncology Otorhinolaryngology

Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial

By MedXY 02/25/2026

This review analyzes the Phase 3 NIVOPOST-OP trial, demonstrating that adding nivolumab to postoperative chemoradiotherapy significantly improves disease-free survival in high-risk SCCHN patients, establishing a potential new therapeutic standard.

news Oncology Otorhinolaryngology

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice

By MedXY 02/19/2026

A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specific baseline comorbidities.

news Oncology Respiratory

Serplulimab Plus Chemotherapy Redefines First-Line Standards in Non-Squamous NSCLC: Results from the ASTRUM-002 Trial

By MedXY 02/19/2026

The Phase 3 ASTRUM-002 trial demonstrates that adding serplulimab to chemotherapy significantly extends progression-free survival in non-squamous NSCLC, though the further addition of a bevacizumab biosimilar (HLX04) did not provide statistically significant incremental benefit.

Hematology-Oncology news

Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia

By MedXY 02/18/2026

A Phase 1 study demonstrates that iTAC-XS15-CLL01, a personalised multipeptide T-cell activator, induces robust immune responses in 95% of CLL patients on BTK inhibitors, offering a potential path to sustainable cancer control and eradication of minimal residual disease.

news Oncology

Breaking Resistance in Gynaecological Clear Cell Carcinoma: Pembrolizumab plus Lenvatinib Achieves 40% Response Rate in LARA Trial

By MedXY 02/18/2026

The Phase 2 LARA trial demonstrates that combining pembrolizumab and lenvatinib yields a 40% objective response rate in recurrent gynaecological clear cell carcinoma, offering a potential new standard for this historically chemo-resistant and microsatellite-stable malignancy.

Hematology-Oncology news

Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL

By MedXY 02/17/2026

The CART19-BE-02 phase 2 trial demonstrates that varnimcabtagene autoleucel, utilizing a unique fractionated dose escalation strategy, achieves an 84.4% MRD-negative complete response rate in adults with relapsed or refractory B-ALL while significantly reducing the incidence of severe neurotoxicity and cytokine release syndrome.

Dermatology news Oncology

Nivolumab Redefines Long-Term Outcomes in Resected High-Risk Melanoma: 9-Year Insights from CheckMate 238

By MedXY 02/05/2026

The final 9-year analysis of the CheckMate 238 trial confirms that adjuvant nivolumab provides a sustained recurrence-free survival advantage over ipilimumab in patients with resected high-risk melanoma, with 44% of patients remaining recurrence-free nearly a decade after treatment.

Diabetes & Endocrinology news

Precision Immunotherapy in Type 1 Diabetes: Baseline Beta-Cell Function as a Predictive Biomarker for Abatacept Efficacy

By MedXY 02/03/2026

A post-hoc analysis reveals that Abatacept significantly delays progression to Stage 2 or 3 Type 1 Diabetes specifically in individuals with higher baseline insulin secretion, marking a breakthrough in precision immunotherapy for early-stage disease.

news Oncology Otorhinolaryngology

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma

By MedXY 01/30/2026

A secondary analysis of the CAPTAIN-1st trial reveals that adding camrelizumab to first-line chemotherapy significantly improves five-year overall survival in RM-NPC, with a 37.8% survival rate and notable benefits linked to rapid EBV DNA clearance.

Dermatology Infectious Diseases news

Dual-Action IgY and Cerium Oxide Nanofibrous Dressings Accelerate Scarless Healing in Infected Wound Models

By MedXY 01/29/2026

Researchers have developed a novel P/G@IYCe dressing combining yolk immunoglobulins and cerium oxide nanoparticles. This synergy effectively neutralizes bacterial pathogens and reactive oxygen species, facilitating rapid, high-quality skin regeneration and significantly reducing scar formation in infected full-thickness wound models.

news Oncology Pediatrics

Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma

By MedXY 01/20/2026

Recent clinical trials establish dinutuximab beta as a cornerstone of neuroblastoma therapy, demonstrating significant survival benefits when combined with chemotherapy in relapsed cases, while clarifying that adding Interleukin-2 to standard consolidation increases toxicity without improving outcomes.